Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. - Wikidata - wikimedia - TriplyDB

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

http://www.wikidata.org/entity/Q34711661

about

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma Pembrolizumab in classical Hodgkin's lymphoma Hodgkin's Lymphoma: A Review of Neurologic Complications Hodgkin lymphoma, version 2.2015.Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up.Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.Role of chemotherapy in Hodgkin's lymphoma.The Evolving Role of Radiotherapy in Early Stage Hodgkin's Lymphoma.Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis.Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma Hodgkin's lymphoma therapy: past, present, and future.Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma.Hodgkin lymphoma.Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Metabolic positron emission tomography imaging in cancer detection and therapy response.Applications of new irradiation modalities in patients with lymphoma: Promises and uncertainties.Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era.Current concepts and controversies in the management of early stage Hodgkin lymphoma.Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts.Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease.The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study.Secondary malignancies across the age spectrum.Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience.Application of metabolic PET imaging in radiation oncology.

P2860

Q24234975-DCA71BF7-C925-42F0-98B6-DCDBEC1A0E5E Q28079273-5F31507E-51B0-44D8-8CE0-747FDA6F1303 Q30479037-C2BE5341-371B-42E7-AC27-CD3BA054A72B Q30769157-1B718D0F-E10D-44F8-8798-2E7543C8469A Q31138212-A130B48C-B26D-4D55-B550-564F54A75E0D Q33406827-711A7FB1-B86D-4F73-8283-2A58BCFA5A0C Q33442092-FF6BEB9F-2824-45B0-A391-FE00972165D9 Q33761103-DFFA82ED-A4D8-4F81-B423-B3435503166B Q33778385-3B7B8FF2-A256-4A95-BCD1-E85F04206A20 Q33844660-ED323BF3-F1BD-4ACB-B259-B288167A6725 Q34173426-7CED6D8B-32AA-4CAF-8F39-4BAEA6ABA204 Q34235785-55686901-FE35-452D-A293-C0B04BF2E101 Q34296914-3A7F8FE0-FFD5-44DA-8A67-275C31006A6F Q34475763-AEB52D0B-17D9-42B3-B47C-5F345648DAA0 Q34495333-0F2C490D-9992-43F2-9C7D-77019132AC0E Q34610653-0370882B-5FFE-4939-8226-A6C34D4C7034 Q34640031-F350287A-A15F-43D4-91A5-8364D669C487 Q34643277-8655C3BE-B086-4492-A7D3-A849F974C333 Q34664223-34F31D4F-0CD8-45DA-BDB3-6681615B9DC6 Q34786518-89FEE865-4BD5-4035-A49F-6B958E6DDEBD Q34822846-65FDB8A8-0EF0-4786-BE17-26CA2328C0DE Q35038832-CF290813-17EC-430C-AAFC-379E90A4CB30 Q35038852-B2DC3B59-A83B-44BF-992C-098248686369 Q35469320-1D8DF79D-8FEB-4761-BEFC-4B30B5CA9F52 Q36061643-434AC156-13B9-4FF3-A73A-F68E37E76FD0 Q36117147-E94EB467-ACA6-43C9-9F1E-6F6C34FA8DDC Q36135751-240C7760-A73F-4EBC-8C68-AFE926E092DE Q36400264-1AD659A1-14AC-4FC5-9ED1-B8345C970125 Q36440046-9FBFF7FF-980D-4FF9-93D8-76CC0E0B3CDA Q36673451-FD650F79-6F3A-4395-83BA-4FDAAEDB4351 Q36702397-CFFB2722-90E5-423F-81F1-0DF1FFDE9DDC Q36898355-E7A8DC16-907D-4CA9-A6A9-B1B23FD50CA5 Q37058257-49042906-E854-4601-A30C-5E47E8C37F97 Q37146056-E6CE5C59-9043-4553-B6E1-92A299960251 Q37149757-ABD46711-65DF-4097-9E04-E88098D403FB Q37330650-7B794EC5-66D1-4039-9959-C524113727AF Q37379773-E24451A7-1EDD-4BBE-8D60-25E7FC91C957 Q37383554-856C0621-226E-4243-B387-39E6FF8E802A Q37563122-AC0E9BF4-6CCA-44FC-93E5-D00DED696E3B Q37580845-862A8F28-B050-475F-9D05-2BBC81A3D930

P2860

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

http://www.wikidata.org/entity/Q34711661

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@ast

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@en

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@nl

type

label

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@ast

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@en

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@nl

prefLabel

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@ast

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@en

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

@nl

P1433

Q34711661-FE5316DE-20FB-4ECB-8F56-E27D52E6E840

P1476

Q34711661-9CF411D4-1FB8-48D4-B60A-BC4EBBC84C6D

P2093

Q34711661-0100CFD9-8CF2-4922-B247-0CC49EF18858

Q34711661-042A7287-E397-4BD6-8ABE-714C3EEA62BF

Q34711661-1B1CF2BB-4E4D-41F4-BA58-284B8C296C58

Q34711661-1F49EDD1-D7B7-46D1-98B7-87EA239E154A

Q34711661-1FB12B62-0851-48D8-A2BA-0EC31DCE1335

Q34711661-2375F5A4-DA7D-4BC5-8980-A54EA6359E4B

Q34711661-2399BBAF-FF74-4574-8D2B-0FB33F7EE071

Q34711661-23B77B67-2728-4E80-BE21-4A66B1D6A813

Q34711661-2D324379-3A1A-4CFA-8272-CD8F644CB714

Q34711661-2DBEDC2B-A16F-4E8F-95A4-026AEF80AF0A

P304

Q34711661-FDBCA901-31BC-4E7E-AF5B-3E36778F3326

P31

Q34711661-4D730EF3-FFA4-4552-B2CA-C7F8AE150FEF

P356

Q34711661-6A1119E2-D171-4F95-A173-521EE7923594

P407

Q34711661-8100A7CF-5B72-4EFB-B833-156813A3FE77

P433

Q34711661-1A78ECB5-9B52-4A1D-8BBF-33B633D8D43C

P478

Q34711661-AC85F130-A702-45FF-AB2A-2D6153347511

P50

Q34711661-9DB742B3-6478-4F79-8328-7DBACE8C2979

Q34711661-A019EAD3-D54D-4003-ABE0-E6A8B87CED25

Q34711661-DAAA9650-7A82-4A4E-A8C3-2A1E6353EBB7

Q34711661-E4B90159-A756-4A39-B715-35B678F5B832

P577

Q34711661-1542A79C-5596-4CDD-BCFD-9EE7CCD73E3F

P698

Q34711661-51F43A10-6232-4462-8409-C16CD4B459B5

P921

Q34711661-D56394EB-C638-4DED-AB78-DA397CD6529F

P356

P1433

The New England Journal of Medicine

P1476

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

@en

P2093

Anton Hagenbeek

http://www.w3.org/2001/XMLSchema#string

Brigitte Vié

http://www.w3.org/2001/XMLSchema#string

Chantal Rieux

http://www.w3.org/2001/XMLSchema#string

Christian Carrie

http://www.w3.org/2001/XMLSchema#string

Christophe Fermé

http://www.w3.org/2001/XMLSchema#string

EORTC-GELA H8 Trial

http://www.w3.org/2001/XMLSchema#string

Eric Van den Neste

http://www.w3.org/2001/XMLSchema#string

Evert M Noordijk

http://www.w3.org/2001/XMLSchema#string

Fernando Viseu

http://www.w3.org/2001/XMLSchema#string

Françoise Berger

http://www.w3.org/2001/XMLSchema#string

P304

1916-1927

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA064601

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P50

Michel Henry-Amar

Hanneke C Kluin-Nelemans

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17989384

http://www.w3.org/2001/XMLSchema#string

P921